Press Release Details

Cerus Corporation to Present at the Rodman & Renshaw Conference

October, 13 2005

CONCORD, Calif.--(BUSINESS WIRE)--Oct. 13, 2005--Cerus Corporation (Nasdaq:CERS) today announced that the company will present at Rodman & Renshaw's 7th Annual TechVest Healthcare Conference on Wednesday, November 9, 2005 at 9:25 am edt. Claes Glassell, president and CEO, William J. Dawson, vice president and CFO, and David N. Cook, vice president of research and development will provide an overview of the company.

The conference is being held at the Palace Hotel in New York, NY. Interested parties may access a live or archived Internet broadcast of the presentation at The presentation will be archived for 90 days.

About Cerus

Cerus Corporation is developing novel products for cancer, infectious disease and blood safety based on multiple, innovative technology platforms. The company is building a pipeline of next generation cancer immunotherapies by combining its proprietary attenuated Listeria vector platform with promising disease antigens. These products are designed to stimulate innate and T cell immune pathways, generating highly potent anti-tumor responses. The company's KBMA vaccine technology has potential broad applications against multiple pathogens. Cerus is applying its Helinx technology to develop the INTERCEPT Blood System, which is designed to enhance the safety of blood components through pathogen inactivation. The company's strategy is to leverage the broad potential of its technologies and products through alliances. Cerus' partners to date include MedImmune and Johns Hopkins University for cancer immunotherapy, and Baxter International and BioOne for the INTERCEPT Blood System.

Statements in this news release regarding potential efficacy and safety of products, product development and commercial potential are forward-looking statements that involve risks and uncertainties. Actual results could differ materially from the above forward-looking statements as a result of certain factors, including the risks and uncertainties inherent in developing biotechnology products based on new technologies, the timing and results of clinical trials and other development activities, market acceptance of Cerus Corporation's products, actions by regulatory authorities at any stage of the development process, the availability of governmental or third party reimbursement for the use of Cerus Corporation's products, the size of the market for the company's products, competitive conditions, manufacturing capabilities, and other factors discussed in the company's Form 10-K/A for fiscal 2004, as well as in other reports filed from time to time with the Securities and Exchange Commission. The company assumes no obligation to update any forward-looking statements.

    CONTACT: Cerus Corporation
             Ruey-Li Hwang, 925-288-6017

    SOURCE: Cerus Corporation

    Global Headquarters

  • 1220 Concord Avenue
  • Concord, CA US 94520
  • +1 925.288.6000

    European Headquarters

  • Stationsstraat 79-D
  • 3811 MH Amersfoort, Netherlands
  • +31 (0) 33 49 60 600